ClinicalTrials.gg
CompletedNCT03592121Updated Mar 12, 2020Results posted

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

An Early Phase 1 interventional study of AB-101 and Placebo in Sexual Dysfunction, Sexual Arousal Disorder and Sexual Dysfunction, Physiological, sponsored by Applied Biology, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-12.

Sponsored by Applied Biology, Inc. · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Sexual Dysfunction, Physiological with a site in United States — 16 open to participants now, 17 under way, none of them phase 3. Sexual Dysfunction, Physiological · United States.

Enrollment
101st of 107
3 · median 60
Started
2018
with 5 others
Phase 1
2 of 127
none open now
Registered
83rd of 127
by date

Among the 127 studies in Sexual Dysfunction, Physiological with a site in United States, this one is the 101st largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2018, is one of 2 in phase 1, and was the 83rd registered.

Sexual Dysfunction, Physiological

385 studies on the registry are indexed under Sexual Dysfunction, Physiological; 72 are open to participants now.

Browse Sexual Dysfunction, Physiological studies →

Open to participants now

16 of the 127 studies in Sexual Dysfunction, Physiological with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Sexual Dysfunction, Physiological studies recruiting now, 23 (50%) set no upper age limit and 20 (43%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Sexual Dysfunction, Physiological with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.

Read the detailed description

Approximately, 80% of breast cancer survivors undergoing will suffer from a permanent reduced reduction in nipple sensitivity and associated lowerdecrease in sexual quality of life. Currently, there are no treatments for restoring nipple sensitivity and the associatedto improve lower sexual quality of life this condition. It would thus be of great clinical benefit to post breast surgery patients if a provide a new safe and , effective , topical , on-demand, treatment for this condition can be developed.

03

Conditions studied

  • Sexual Dysfunction
  • Sexual Arousal Disorder
  • Sexual Dysfunction, Physiological
  • Breast Cancer
  • Nipple Disorder
  • Neuropathy
  • Cancer of Breast

Keywords

  • Nipple Neuropathy, Cancer Survivor
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female breast cancer survivor
  • Age: 18 to 70
  • First diagnosed with Stage I or II breast cancer
  • Have had breast surgery: nipple sparring mastectomy or lumpectomy
  • At least 3 years post surgery
  • Nipple neuropathy post breast surgery (change in Llikeart scale >= 3 between pre and post surgery)
  • Baseline nipple sensitivity \<=5 (likeartLikert scale)
  • QoL-BC (>=7)
  • Delayed orgasm ( v4.0) Grade 2
  • One of the following: Delayed orgasm (CTCAE v4.0) Grade 2 and/or Vaginal dryness (CTCAE v4.0) Grade 2 or 3
  • Able to give
  • Currently in a monogamous heterosexual relationship for at least 12 months
  • Sexually active within the last 30 days
  • Willing to engage in sexual activity at least once a month during the duration of the study
  • Willing to use on a regular basis a web based form system to record sexual events i.e., have access to the Internet
  • Willing to use an adequate method of
  • Able to comply with the study requirements for 8 consecutive weeks
  • Able to give informed consent

Exclusion criteria

Exclusion Criteria:

  • Previous adverse event to alpha 1 agonists (oral, nasal, topical, or ocular) or drugs in this class
  • Currently pregnant
  • Nursing within the last 6 months prior to beginning the study
  • History of cardiovascular or cerebrovascular disease, e.g., heart attack, disease of the arteries of the heart, partial heart block, rapid ventricular heartbeat, slow heartbeat, chronic heart failure, severe hardening of the arteries, blood clot in an artery
  • Actively being treated for breast cancer
  • Changes in chronic medication for oncology, cardiology, or endocrinology in past 12 months
  • Uncontrolled or severe hypertension
  • Decreased oxygen in the tissues or blood
  • Active inflammation of the liver
  • Acute inflammation of the pancreas
  • Overactive thyroid gland
  • Acidosis
  • Diabetes
  • Spinal cord injury
  • Nipple dermatitis
  • Regional complex pain syndrome
  • Use of any hypertensive drugs
  • Use of MAO inhibitors
  • Subjects assigned to interventional drug arm and failed to report an increase >=2 from baseline in nipple sensitivity (likert scale) during phase I
  • In partners: sexual dysfunction or erectile dysfunction
  • Currently enrolled in any other medical study or has been enrolled in any medical study in the past 30 days
  • Nipple dermatitis
  • Regional complex pain syndrome
  • Unable to provide consent or make allotted clinical visits
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    AB-101

    Apply to both nipple/areola regions approximately 1 hour prior to sexual activity

    Drug: AB-101

  • Placebo comparator
    Placebo

    Apply to both nipple/areola regions approximately 1 hour prior to sexual activity

    Drug: Placebo

Interventions

  • DrugAB-101

    Apply approximately 1 hour prior to sexual activity

    Also known as: Phenylephrine

  • DrugPlacebo

    Apply approximately 1 hour prior to sexual activity

    Also known as: Vehicle Solution

06

What researchers measure

Primary outcomes

  1. Change in Delayed Orgasm Grade

    Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0 Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax. This is a binary grading system: Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship

    Time frame: [baseline, week 8]

07

Results

Posted Mar 12, 2020

Participant flow

Participant flow — Overall Study
MilestoneAB-101Placebo
Started30
Completed30
Not completed00

Outcome measures

PrimaryChange in Delayed Orgasm Grade

Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0 Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax. This is a binary grading system: Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship

Time frame:
[baseline, week 8]
Reported as:
Mean · Grade
Change in Delayed Orgasm Grade
GradeAB-101Placebo
Change in Delayed Orgasm Grade-0.33 ± 0.58—

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AB-1010/3 (0%)0/3 (0%)0/3 (0%)
Placebo———

Baseline characteristics

We were unable to recruit a sufficient number of subjects.

Age, Categorical
Age, Categorical(Participants)AB-101PlaceboTotal
<=18 years000
Between 18 and 65 years303
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)AB-101PlaceboTotal
Female303
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AB-101PlaceboTotal
Hispanic or Latino0—0
Not Hispanic or Latino3—3
Unknown or Not Reported0—0
Region of Enrollment
Region of Enrollment(participants)AB-101PlaceboTotal
United States3—3
Delayed Orgasm Grade (CTCAE v4.0)
Delayed Orgasm Grade (CTCAE v4.0)(Grade)AB-101PlaceboTotal
Mean0.67 ± 0.58—0.67 ± 0.58
08

Study locations

1 site
  • Southern CA Center for Sexual Health and Survivorship Medicine
    Newport Beach, California 92663, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Oct 2019, 15 months.

Results were first posted in Mar 2020, 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2018
First posted
Jul 19, 2018
StartActual
Jul 9, 2018
Primary completionActual
Oct 12, 2019
CompletionActual
Oct 12, 2019
Results first posted
Mar 12, 2020
Last update
Mar 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03592121
Responsible party
Sponsor
First posted
Jul 19, 2018
Start date
Jul 9, 2018
Primary completion
Oct 12, 2019
Completion
Oct 12, 2019
Results posted
Mar 12, 2020
Last update
Mar 12, 2020

Study contacts

Michael Krychman, MD
principal investigator · Southern CA Center for Sexual Health and Survivorship Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AB-101

Start the discussion